MICB and neoplasm: Similarly, histone deacetylase inhibitor MS-275 enhanced the protein levels of immunostimulatory molecules [MHC class I polypeptide-related sequence B (MICB) and HSP70] in EVs derived from HCC cells, increasing the cytotoxicity of NK cells and anti-tumor response (118).